MedTrace Logo

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

NCT05563272 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-07-10

No results posted yet for this study

Summary

A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Conditions

Interventions

DIAGNOSTIC_TEST

89Zr-girentuximab for PET/CT imaging of CAIX positive tumors

On Day 0, participants will receive a single administration of 89Zr-girentuximab (37 Megabecquerel (MBq) \[1mCi\] ± 10%, containing a mass dose of 10 mg of girentuximab).

Sponsors & Collaborators

  • Telix Pharmaceuticals (Innovations) Pty Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-06
Primary Completion
2025-05-09
Completion
2025-05-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563272 on ClinicalTrials.gov